Compare CLDI & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLDI | XXII |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | 29 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.3M |
| IPO Year | N/A | 2011 |
| Metric | CLDI | XXII |
|---|---|---|
| Price | $0.16 | $6.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 398.0K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.96 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,832,530.00 |
| Revenue This Year | N/A | $370.28 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $0.27 |
| 52 Week High | $7.32 | $11.37 |
| Indicator | CLDI | XXII |
|---|---|---|
| Relative Strength Index (RSI) | 28.84 | 91.43 |
| Support Level | N/A | $1.55 |
| Resistance Level | $0.20 | $6.86 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | 0.00 | 0.42 |
| Stochastic Oscillator | 24.94 | 87.94 |
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.